|
Delayed
Hong Kong S.E.
01:49:09 29/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 17.93 HKD | -1.43% |
|
+0.78% | +31.72% |
| 10-27 | Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading | MT |
| 10-26 | Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4% | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,585 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 31.78% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 2,128 | 2,205 | 2,348 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 52.36% | 3.61% | 6.49% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -10.4x | -10.4x | -15.8x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 5.03x | 6.6x | 6.07x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.3x | -51.63x | 0.5x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 5.97x | 4.72x | 3.62x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 4.92x | 4.02x | 3.29x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -7.54x | -9.26x | -17.1x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -7.48x | -9.35x | -14.3x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -12.1x | -12.3x | -19.2x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -8.25% | -8.1% | -5.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.209 | -2.214 | -1.46 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 432.7 | 548.2 | 713.6 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -282.2 | -238 | -137 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -284.6 | -235.8 | -164.5 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -240.7 | -219.6 | -157.1 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -457.7 | -380.8 | -237.7 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 23.03 | 23.03 | 23.03 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,266 | - | - |
| Announcement Date | 01/03/22 | 01/03/23 | 27/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 29.58x | 7.09x | 18.77x | 2.12% | 447.5B | |
| Weighted average by Cap. | 35.27x | 8.35x | 20.48x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- 9688 Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
